Intercept Pharmaceuticals Inc (ICPT) 283.20 $ICPT
Intercept Pharmaceuticals Releases Data on Lead Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:24PM CDT
Intercept Pharmaceuticals (ICPT) released post-hoc analyses from the phase IIb trial, FLINT, on lead candidate obeticholic acid (OCA) in patients suffering from NASH.
BIIB: 401.71 (-28.57), HZNP: 31.75 (+0.97), ICPT: 283.20 (-2.22)
Genfit Digs Even Deeper to Find Hidden Benefit in Fatty Liver Drug
at The Street - Fri Apr 24, 8:12AM CDT
None of the sugar-coated analyses presented at a meeting suggest the eventual outcome of Genfit's phase III study will be any better than the phase II study.
ICPT: 283.20 (-2.22)
Intercept Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution and Cirrhosis Prevention in High-Risk NASH Patients
GlobeNewswire - Thu Apr 23, 2:35AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) announced today the availability of additional post-hoc analyses from the Phase 2b FLINT trial of obeticholic acid (OCA) in patients with nonalcoholic steatohepatitis (NASH) at the International Liver Congress 2015, the 50 Annual Meeting of the European Association for the Study of the Liver (EASL), being held in Vienna, Austria, from April 22-26, 2015. The poster entitled "Obeticholic Acid for NASH: Benefits in a High-Risk Subgroup and the Effects of Concomitant Stain Use" (late-breaker ePoster LP18) is currently available for viewing and will be presented in Room A-09 at 3:30 p.m. CET on Saturday April 25, 2015. The senior authors include Dr. Brent Neuschwander-Tetri, of St Louis University and Dr. Arun Sanyal, former President of the American Association of the Study of Liver Disease, from the NASH Clinical Research Network that conducted the trial.
ICPT: 283.20 (-2.22)
Trade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's Strong On High Relative Volume Stock
at The Street - Fri Apr 17, 9:10AM CDT
Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a strong on high relative volume candidate
ICPT: 283.20 (-2.22)
Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015
GlobeNewswire - Mon Apr 13, 5:01AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, announced today that several abstracts evaluating obeticholic acid (OCA) in patients with primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH) will be presented at the International Liver Congress 2015, the 50th Annual Meeting of the European Association for the Study of the Liver (EASL), being held in Vienna, Austria, from April 22-26, 2015. Intercept also announced abstracts relating to PBC to be presented by the Global PBC Study Group and the UK-PBC Group at EASL.
ICPT: 283.20 (-2.22)
Critical Alerts For Mobileye NV, Las Vegas Sands, Intercept Pharmaceuticals, AT&T and Zoe's Kitchen Released By InvestorsObserver
PR Newswire - Fri Apr 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MBLY, LVS, ICPT, T and ZOES.
ZOES: 34.67 (+0.83), T: 34.01 (-0.22), ICPT: 283.20 (-2.22), LVS: 55.25 (+0.13), MBLY: 47.62 (+0.01)
Why Intercept Pharmaceuticals Inc. Exploded Higher in March
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 08, 8:04AM CDT
What: Shares of Intercept Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing novel drugs to treat chronic liver and intestinal diseases, exploded higher by 27% in March, according to data from S&P Capital IQ ,...
ICPT: 283.20 (-2.22)
Regulus Soars As AstraZeneca Grabs NASH Drug Rights
at Investor's Business Daily - Tue Apr 07, 6:41PM CDT
Regulus Therapeutics (RGLS) stock leapt Tuesday night as AstraZeneca (AZN) took its NASH fatty liver disease candidate for testing as part of their microRNA alliance. They join a crowded field of drugmakers developing treatments and making...
GILD: 103.69 (-1.52), CNAT: 6.66 (-0.15), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), ICPT: 283.20 (-2.22), ABBV: 66.07 (+1.82), RGLS: 17.49 (-0.80)
Genfit: Refuting Bearish Arguments About Genfit's Results
Logribel Biostocks - at Seeking Alpha - Mon Apr 06, 5:58PM CDT
ICPT: 283.20 (-2.22)
Intercept Pharma completes equity offering
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 4:20PM CDT
ICPT: 283.20 (-2.22)
Intercept Pharmaceuticals Announces Completion of Public Offering
GlobeNewswire - Mon Apr 06, 3:10PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, today announced the completion of its previously announced underwritten public offering of 1,200,000 shares of its common stock. In addition, Intercept today announced the completion of the sale of an additional 130,865 shares of its common stock pursuant to the partial exercise of the underwriters' option to purchase additional shares.
ICPT: 283.20 (-2.22)
Nonalcoholic Steatohepatitis Treatment Landscape Discussed in New FirstWord Research Report Published at MarketPublishers.com
PRWeb - Thu Apr 02, 12:02PM CDT
The treatment of nonalcoholic steatohepatitis (NASH) is expected to witness drastic changes in the years to come; a slew of novel therapies are competing with one another to become the first approved therapy option for NASH.
ICPT: 283.20 (-2.22), TBRA: ()
Insider Trading Alert - ICPT, WMB And FII Traded By Insiders
at The Street - Thu Apr 02, 11:19AM CDT
Stocks with insider trader activity include ICPT, WMB and FII
FII: 34.73 (+0.06), ICPT: 283.20 (-2.22), WMB: 52.57 (+0.02)
Genfit Is An Even Bet To Recover In The NASH Race
Clinically Sound Investor - at Seeking Alpha - Tue Mar 31, 3:43PM CDT
RPTP: 10.81 (+0.10), GILD: 103.69 (-1.52), CNAT: 6.66 (-0.15), ICPT: 283.20 (-2.22)
Healthcare Hedge Fund Orbimed's Top Picks And New Move
Insider Monkey - Seeking Alpha - Tue Mar 31, 10:37AM CDT
By Usman Rafi According to a Schedule 13D Form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT ) by about 14%. The fund...
BIIB: 401.71 (-28.57), ICPT: 283.20 (-2.22), AMGN: 167.91 (-1.26), BMY: 65.80 (-0.20)
InsiderInsights.com Daily Round Up 3/30/15: VEEV, VNCE, PRSS, OGS
InsiderInsights - at Seeking Alpha - Tue Mar 31, 9:55AM CDT
GIII: 118.53 (+1.90), KIRK: 24.35 (+0.50), LNG: 77.29 (-1.35), VNCE: 18.94 (-0.30), UE: 23.40 (-0.09), AET: 108.82 (-0.08), VEEV: 27.17 (-0.24), PRSS: 3.98 (+0.10), WIW: 11.55 (+0.04), DVA: 83.91 (+0.50), PRE: 129.04 (unch), ARMK: 31.66 (+0.20), CPF: 22.80 (-0.38), FSB: 20.90 (+0.15), PHII: 31.74 (-0.26), RIT: 13.04 (unch), ICPT: 283.20 (-2.22), OGS: 43.00 (+0.52), ALCO: 47.11 (-0.65), WIA: 11.69 (+0.03)
Genfit: Misunderstandings And Propaganda About Phase 2b Results Provide A Good Entry Point
Logribel Biostocks - at Seeking Alpha - Tue Mar 31, 9:10AM CDT
ICPT: 283.20 (-2.22)
Intercept Pharma prices equity offering
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 8:22AM CDT
ICPT: 283.20 (-2.22)
Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Mar 31, 8:13AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, today announced the pricing of an underwritten public offering of 1,200,000 shares of its common stock. The underwriters intend to offer the shares of common stock from time to time for sale in one or more transactions on The Nasdaq Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. Intercept granted the underwriters 30-day option to purchase up to an additional 180,000 shares of common stock, on the same terms and conditions.
ICPT: 283.20 (-2.22)
Genfit's French Fans Fume Following Failure of Fatty Liver Drug
at The Street - Tue Mar 31, 7:51AM CDT
French investors holding shares of Genfit are having trouble coping with the failure of the company's fatty liver disease drug GFT505.
ICPT: 283.20 (-2.22), TWTR: 50.82 (-0.59)
Intercept Pharmaceuticals Releases Data on Lead Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:24PM CDT
Intercept Pharmaceuticals (ICPT) released post-hoc analyses from the phase IIb trial, FLINT, on lead candidate obeticholic acid (OCA) in patients suffering from NASH.
BIIB: 401.71 (-28.57), HZNP: 31.75 (+0.97), ICPT: 283.20 (-2.22)
Genfit Digs Even Deeper to Find Hidden Benefit in Fatty Liver Drug
at The Street - Fri Apr 24, 8:12AM CDT
None of the sugar-coated analyses presented at a meeting suggest the eventual outcome of Genfit's phase III study will be any better than the phase II study.
ICPT: 283.20 (-2.22)
Intercept Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution and Cirrhosis Prevention in High-Risk NASH Patients
GlobeNewswire - Thu Apr 23, 2:35AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) announced today the availability of additional post-hoc analyses from the Phase 2b FLINT trial of obeticholic acid (OCA) in patients with nonalcoholic steatohepatitis (NASH) at the International Liver Congress 2015, the 50 Annual Meeting of the European Association for the Study of the Liver (EASL), being held in Vienna, Austria, from April 22-26, 2015. The poster entitled "Obeticholic Acid for NASH: Benefits in a High-Risk Subgroup and the Effects of Concomitant Stain Use" (late-breaker ePoster LP18) is currently available for viewing and will be presented in Room A-09 at 3:30 p.m. CET on Saturday April 25, 2015. The senior authors include Dr. Brent Neuschwander-Tetri, of St Louis University and Dr. Arun Sanyal, former President of the American Association of the Study of Liver Disease, from the NASH Clinical Research Network that conducted the trial.
ICPT: 283.20 (-2.22)
Trade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's Strong On High Relative Volume Stock
at The Street - Fri Apr 17, 9:10AM CDT
Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a strong on high relative volume candidate
ICPT: 283.20 (-2.22)
Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015
GlobeNewswire - Mon Apr 13, 5:01AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, announced today that several abstracts evaluating obeticholic acid (OCA) in patients with primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH) will be presented at the International Liver Congress 2015, the 50th Annual Meeting of the European Association for the Study of the Liver (EASL), being held in Vienna, Austria, from April 22-26, 2015. Intercept also announced abstracts relating to PBC to be presented by the Global PBC Study Group and the UK-PBC Group at EASL.
ICPT: 283.20 (-2.22)
Critical Alerts For Mobileye NV, Las Vegas Sands, Intercept Pharmaceuticals, AT&T and Zoe's Kitchen Released By InvestorsObserver
PR Newswire - Fri Apr 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MBLY, LVS, ICPT, T and ZOES.
ZOES: 34.67 (+0.83), T: 34.01 (-0.22), ICPT: 283.20 (-2.22), LVS: 55.25 (+0.13), MBLY: 47.62 (+0.01)
Why Intercept Pharmaceuticals Inc. Exploded Higher in March
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 08, 8:04AM CDT
What: Shares of Intercept Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing novel drugs to treat chronic liver and intestinal diseases, exploded higher by 27% in March, according to data from S&P Capital IQ ,...
ICPT: 283.20 (-2.22)
Regulus Soars As AstraZeneca Grabs NASH Drug Rights
at Investor's Business Daily - Tue Apr 07, 6:41PM CDT
Regulus Therapeutics (RGLS) stock leapt Tuesday night as AstraZeneca (AZN) took its NASH fatty liver disease candidate for testing as part of their microRNA alliance. They join a crowded field of drugmakers developing treatments and making...
GILD: 103.69 (-1.52), CNAT: 6.66 (-0.15), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), ICPT: 283.20 (-2.22), ABBV: 66.07 (+1.82), RGLS: 17.49 (-0.80)
Genfit: Refuting Bearish Arguments About Genfit's Results
Logribel Biostocks - at Seeking Alpha - Mon Apr 06, 5:58PM CDT
ICPT: 283.20 (-2.22)
Intercept Pharma completes equity offering
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 4:20PM CDT
ICPT: 283.20 (-2.22)
Intercept Pharmaceuticals Announces Completion of Public Offering
GlobeNewswire - Mon Apr 06, 3:10PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, today announced the completion of its previously announced underwritten public offering of 1,200,000 shares of its common stock. In addition, Intercept today announced the completion of the sale of an additional 130,865 shares of its common stock pursuant to the partial exercise of the underwriters' option to purchase additional shares.
ICPT: 283.20 (-2.22)
Nonalcoholic Steatohepatitis Treatment Landscape Discussed in New FirstWord Research Report Published at MarketPublishers.com
PRWeb - Thu Apr 02, 12:02PM CDT
The treatment of nonalcoholic steatohepatitis (NASH) is expected to witness drastic changes in the years to come; a slew of novel therapies are competing with one another to become the first approved therapy option for NASH.
ICPT: 283.20 (-2.22), TBRA: ()
Insider Trading Alert - ICPT, WMB And FII Traded By Insiders
at The Street - Thu Apr 02, 11:19AM CDT
Stocks with insider trader activity include ICPT, WMB and FII
FII: 34.73 (+0.06), ICPT: 283.20 (-2.22), WMB: 52.57 (+0.02)
Genfit Is An Even Bet To Recover In The NASH Race
Clinically Sound Investor - at Seeking Alpha - Tue Mar 31, 3:43PM CDT
RPTP: 10.81 (+0.10), GILD: 103.69 (-1.52), CNAT: 6.66 (-0.15), ICPT: 283.20 (-2.22)
Healthcare Hedge Fund Orbimed's Top Picks And New Move
Insider Monkey - Seeking Alpha - Tue Mar 31, 10:37AM CDT
By Usman Rafi According to a Schedule 13D Form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT ) by about 14%. The fund...
BIIB: 401.71 (-28.57), ICPT: 283.20 (-2.22), AMGN: 167.91 (-1.26), BMY: 65.80 (-0.20)
InsiderInsights.com Daily Round Up 3/30/15: VEEV, VNCE, PRSS, OGS
InsiderInsights - at Seeking Alpha - Tue Mar 31, 9:55AM CDT
GIII: 118.53 (+1.90), KIRK: 24.35 (+0.50), LNG: 77.29 (-1.35), VNCE: 18.94 (-0.30), UE: 23.40 (-0.09), AET: 108.82 (-0.08), VEEV: 27.17 (-0.24), PRSS: 3.98 (+0.10), WIW: 11.55 (+0.04), DVA: 83.91 (+0.50), PRE: 129.04 (unch), ARMK: 31.66 (+0.20), CPF: 22.80 (-0.38), FSB: 20.90 (+0.15), PHII: 31.74 (-0.26), RIT: 13.04 (unch), ICPT: 283.20 (-2.22), OGS: 43.00 (+0.52), ALCO: 47.11 (-0.65), WIA: 11.69 (+0.03)
Genfit: Misunderstandings And Propaganda About Phase 2b Results Provide A Good Entry Point
Logribel Biostocks - at Seeking Alpha - Tue Mar 31, 9:10AM CDT
ICPT: 283.20 (-2.22)
Intercept Pharma prices equity offering
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 8:22AM CDT
ICPT: 283.20 (-2.22)
Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Mar 31, 8:13AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases, today announced the pricing of an underwritten public offering of 1,200,000 shares of its common stock. The underwriters intend to offer the shares of common stock from time to time for sale in one or more transactions on The Nasdaq Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. Intercept granted the underwriters 30-day option to purchase up to an additional 180,000 shares of common stock, on the same terms and conditions.
ICPT: 283.20 (-2.22)
Genfit's French Fans Fume Following Failure of Fatty Liver Drug
at The Street - Tue Mar 31, 7:51AM CDT
French investors holding shares of Genfit are having trouble coping with the failure of the company's fatty liver disease drug GFT505.
ICPT: 283.20 (-2.22), TWTR: 50.82 (-0.59)
